Summarising an eventful H1'24 Many players in the Parkinson's therapy game.
We make minor changes to adjusted EBITA for 2024E-26E ahead of Q2.
Verve (formerly MGI – Media and Games Invest) has announced the acquisition of Jun Group for €170m (...
The European Medicines Agency (EMA) has approved Cereno Scientific’s Clinical Trial Application (CTA...
Clavister could provide cybersecurity to Thales' SOTAS communication system A tangible revenue case ...
Redeye retains its positive view of Fortnox. While management should have clarified it was talking a...
Biovica records IVD test sales in Q4, which are higher than Q1-Q3, and research test sales have incr...
Redeye comments on the news that the company’s complementary clinical study TRIAC II, which focused ...
Redeye provides a comment on the outcome in Scandinavian ChemoTech’s rights issue.
Redeye comments on Verve’s acquisition of Jun Group, which strengthens its position on the demand si...
The company changed its strategy and abandons its plans to build 600MW of own wind power capacity.
Redeye comments on Fluoguide raising cSEK60m through a directed share issue.
Marknadens nedgång träffar till slut med full kraft, så ledningen revar seglen och vi sänker prognos...
Q2 report due 18 July We forecast SEK 561m net sales, SEK 81m EBITA Fair value range raised to SEK 4...
Q2e: sales +18% and EBITDA +38% y-o-y We raise our EBITDA estimates by 10-6% on '24e-'26e Positive E...
